On August 18, 2026, Tonix Pharmaceuticals Holding Corp. appointed President and CEO Dr. Seth Lederman as Interim Chief Medical Officer. Dr. Lederman will continue serving in his existing roles as President, CEO, and Chairman of the Board. This appointment is an internal administrative change with no impact on corporate strategy or financial condition. Tonix Pharmaceuticals Holding Corp. operates in the biopharmaceutical industry, focusing on the development of immunotherapies for autoimmune diseases.
